Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMimi LoTFTimothy T. FerngCSCatherine C. Smith

Discussion

Loading...

Member takes

Overview

Analysis shows improved treatment outcomes with Blinatumomab in adult B-cell acute lymphoblastic leukemia, indicating better remission rates.

Key Points

  • The addition of Blinatumomab results in an 82% complete remission rate after the first chemotherapy cycle, indicating its efficacy when used alongside traditional treatment.
  • Chemotherapy combined with Blinatumomab significantly improves remission outcomes, with a notable 94% complete remission rate after initial cycles of treatment.
  • Observational analysis of 22 adult patients receiving modification of hyperCVAD and Blinatumomab reveals potential benefits for both high-risk and standard-risk B-ALL patients.
  • These findings stress the need for further optimization of treatment strategies for high-risk patients to enhance long-term survival and minimize relapse.

Cite This Study

Lo et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4e3https://doi.org/10.1182/blood-2025-6861
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens2025 · 1 citations
  2. 2Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia2025
  3. 3Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis2025 · 2 citations
  4. 4Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.2025 · 1 citations
  5. 5Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia2025 · 1 citations